NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis $0.72 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.73 +0.01 (+1.46%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enlivex Therapeutics Stock (NASDAQ:ENLV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enlivex Therapeutics alerts:Sign Up Key Stats Today's Range$0.72▼$0.7450-Day Range$0.70▼$1.2052-Week Range$0.66▼$2.10Volume111,983 shsAverage Volume234,047 shsMarket Capitalization$170.32 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingHold Company Overview Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings. The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system. Allocetra is currently being evaluated in clinical trials for indications such as sepsis, acute respiratory distress syndrome (ARDS), and cytokine storm associated with COVID-19. Enlivex’s pipeline also explores the potential of macrophage-based treatments to reduce complications in stem cell transplantation and support cancer therapies by mitigating treatment-related hyperinflammation. Enlivex collaborates with academic medical centers and contract research organizations across North America and Europe to advance its clinical programs. The management team brings expertise in immunology, cell therapy manufacturing, and regulatory affairs, positioning the company to scale production and pursue global regulatory approvals. Enlivex continues to build strategic partnerships aimed at broadening access to its cell-based immunotherapies for patients facing severe inflammatory disorders.AI Generated. May Contain Errors. Read More Enlivex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreENLV MarketRank™: Enlivex Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 570th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEnlivex Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialEnlivex Therapeutics has a consensus price target of $16.50, representing about 2,199.7% upside from its current price of $0.72.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($0.08) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 1.13, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 1.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News SentimentN/A News SentimentEnlivex Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.MarketBeat FollowsOnly 1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENLV Stock News HeadlinesEnlivex Therapeutics (NASDAQ:ENLV) Shares Down 3.2% - Should You Sell?May 19, 2026 | americanbankingnews.comEnlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisMay 18, 2026 | globenewswire.comThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off.May 26 at 1:00 AM | Weiss Ratings (Ad)Enlivex Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 15, 2026 | globenewswire.comEnlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency ExchangeApril 30, 2026 | globenewswire.comEnlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 MillionApril 28, 2026 | globenewswire.comEnlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World CongressApril 23, 2026 | globenewswire.comEnlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisApril 21, 2026 | globenewswire.comSee More Headlines ENLV Stock Analysis - Frequently Asked Questions How have ENLV shares performed this year? Enlivex Therapeutics' stock was trading at $0.7032 at the beginning of 2026. Since then, ENLV shares have increased by 2.0% and is now trading at $0.7175. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) posted its quarterly earnings data on Friday, November, 14th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.03. When did Enlivex Therapeutics IPO? Enlivex Therapeutics (ENLV) raised $38 million in an initial public offering (IPO) on Wednesday, July 30th 2014. The company issued 3,200,000 shares at $11.00-$13.00 per share. Who are Enlivex Therapeutics' major shareholders? Top institutional shareholders of Enlivex Therapeutics include Bank of America Corp DE (0.05%) and Renaissance Technologies LLC (0.05%). How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META). Company Calendar Last Earnings11/14/2025Today5/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, ENLV's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENLV CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees70Year Founded2012Price Target and Rating Average Price Target for Enlivex Therapeutics$16.50 High Price Target$20.00 Low Price Target$13.00 Potential Upside/Downside+2,199.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.24 billion Net MarginsN/A Pretax MarginN/A Return on Equity248.08% Return on Assets206.39% Debt Debt-to-Equity RatioN/A Current Ratio193.24 Quick Ratio193.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.15 per share Price / Book0.09Miscellaneous Outstanding Shares237,380,000Free Float208,231,000Market Cap$170.32 million OptionableOptionable Beta1.49 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ENLV) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
